List of Therapeutic Companies in Connecticut - 40

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Altucell, Inc. is a cellular engineering and biotech company backed by sound research and science focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of Diabetes and other autoimmune and neurodegenerative diseases. The company’s proprietary and unique technology overcomes the major barriers to transplantation by a novel strategy utilizing patented micro-encapsulation technology, enabling a transplantable, cell-based therapy that avoids detection and rejection by the immune system.

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

BiologicsMD is developing novel therapeutics and therapeutic-device combinations for the treatment of hair-loss and bone disorders. The company's portfolio of hair cycle stimulators (HCS) are first-in-class treatments that hold the promise to restore hair and prevent hair loss in conditions of alopecia. The core technology relies on targeting physiologically active agents to Type l collagen found in skin and bone. BiologicsMD's targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

Cytogel is a clinical stage bio-pharmaceutical company developing first in class drug candidates from the novel endomorphin family of molecules, that target key pain pathways and alleviate pain. This groundbreaking approach is backed by new technology to deliver treatment to people in pain. Learn how we’re reinventing pain management.

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

GestVision Inc. is a biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women's health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women's health by bringing forth premium products based upon robust scientific discoveries.

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today's precision cancer medicines. Using a novel ‘hold and kill' mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

InveniAI is pioneering AI and machine learning to map and identify breakthrough innovation across industries. Our platform, AlphaMeld, is an Artificial Intelligence (AI) based system that monitors millions of data points every day to identify signals for breakthrough events and provides a first mover advantage in detecting early signals of innovation. It combines human ingenuity and experience, with ceaseless, comprehensive and efficient machine learning that ensures no data point is missed in the pursuit of Alpha signals. AlphaMeld monitors developments daily across industries and rank orders them on their breakthrough potential. Visit www.inveniai.com for more details. Connect with us on Twitter: @Inveni_AI Careers: We are always on the lookout for talent to join our team at our US headquarters in Guilford, CT USA. We are not hiring at present. Please check back or contact us at +1 203 643 8002. Important Note on Our Hiring Process at InveniAI (inveniai) At InveniAI, we are committed to upholding the highest standards of transparency and integrity in everything we do. As part of our dedication to providing a fair and genuine hiring process, we would like to address a crucial matter. It has come to our attention that some individuals may be receiving fraudulent claims requesting money or personal information under the guise of being associated with InveniAI's hiring process. These unauthorized and fraudulent individuals are sending emails from domain names which are similar to our official domain name ‘inveniai.com’. When the recipient clicks on the domain name provided by the fraudulent individuals, they may be redirected to our website (www.inveniai.com). All individuals are requested not to communicate with any email id other than our official email id(s) that end with ‘@inveniai.com’. We want to make it clear that this is not how we operate, and we take this matter very seriously. Our Policy: No Course Registration: We want to emphasize that

Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

LambdaVision is developing the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight.

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more.

Restech offers minimally invasive tools to multiple specialties in order to accurately diagnose and manage reflux, and will continue to create solutions related to the complexity gastric related diseases. Restech’s tools are helping evolve the standard of care for patients with reflux, and fecal incontinence, providing physicians with the necessary data to transform the algorithm of care for tens of millions of patients.

Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing siRNA based drugs that can target otherwise difficult to address disease targets. Our initial gene target is a novel protein that controls metabolic activity/efficiency in the mitochondria. The ability to control mitochondrial activity is significant because > 90% of the energy of the cell comes from the mitochondria. This gene target is a negative regulator. Thus, in the presence of the regulator, metabolism is slowed down and the removal of the regulator safely increases metabolism. We have explored the function of this metabolic regulator in different tissues and disease states and have found that turning off the regulator can have a positive effect in disease treatment. Targeting this gene product creates the opportunity of producing a drug that can treat a wide array of diseases.

NanoViricides, Inc. makesnanoviricides®. Nanoviricides are nanoparticles designed to protect cells from infection by acting as decoys. Virusesbind to nanoviricides instead of cell-surface receptors, gettrapped, and become neutralized.NanoViricides is working to developa treatment for COVID-19 using its nanoviricide®technology.

Neuvotion is developing breakthrough solutions for facilitating and restoring movement. Our approach combines targeted neurostimulation and AI (artificial intelligence) to deliver unparalleled therapeutic value for patients with a movement disorder or impairment from stroke or injury. Neuvotion products allow doctors and therapists to leverage state-of-the-art technology, while monitoring patient progress in-person or remotely.

Our vision: "Cancer treatment in one dose."​ OncoSynergy is a patient-focused biotechnology startup spun out from UCSF and the JLABS South San Francisco incubator. Based in bustling Stamford, Connecticut (~40 mins from NYC), we are creating a new class of cancer medicines to maximize patient survival and quality of life with minimal side effects. We are a small, nimble startup team that launched our first clinical trial in 2020 for glioblastoma (aggressive brain cancer). While we are at the forefront of potential game changing research, please support our patients. They need you to spread awareness far and wide so that more research is being dedicated to devastating cancers like glioblastoma.

Portage Biotech is a clinical-stage immuno-oncology company with a team of scientists, clinicians, and pharma-experienced executives who have a long history of success, collectively contributing to five oncology drug approvals. The company is focused on advancing multi-targeted therapies with the mission to expand the number of treatment options for cancer patients.

Purdue Pharma’s bankruptcy case was heard before the Supreme Court of the United States in December 2023. In June 2024, the Court voted 5-4 against third-party releases contained in the Plan of Reorganization. The decision does nothing to deter us from the twin goals of using settlement dollars for opioid abatement and turning the company into an engine for good. We are reaching back out to creditors and renewing our pursuit of a resolution that delivers billions of dollars of value for opioid abatement and allows the Company to emerge from bankruptcy as a company with a public-minded mission. The Supreme Court’s decision does not affect Purdue’s operational stability or our ability to produce medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners and customers. The company will continue serving patients who rely on our medicines, and working to introduce new medicines that will help save and improve lives.

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.

Recombinant Technologies, LLC, is an emerging biotechnology company focused on developing therapeutics for neurodegenerative diseases. This innovative Bio-Technology company will ... Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South ... Recombinant Technologies and life sciences research enabler and commercialization expert.

Spun out of Yale University in 2020, RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies, and advancing complimentary targeted delivery systems, for the broad-spectrum treatment of viral diseases and cancer. Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune’s products act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance the patients’ intrinsic response to disease. RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD, who are also Scientific Advisors for the company. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on RIG-I. Pyle is also a specialist in RNA structure, and design. In collaboration with Iwasaki, Pyle designed the stem loop RNAs for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds.

Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Thetis Pharmaceuticals is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory disorders. The company was founded in 2011 by ex-Pfizer R&D executives and healthcare investors.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.

Virscio is a specialty translational research organization developing and providing innovative in vivo disease modeling and related preclinical research and development services to meet the preclinical, translational, and regulatory research needs of the pharmaceutical and life sciences industry. We specialize in the fields of ophthalmology, central nervous system, cardiovascular and metabolic related disease and disorders, and have advanced discovery and development programs for a wide range of sponsors, collaborators, and partners around the world, ranging from large pharmaceutical companies and venture-backed biotechnology companies to academic teams seeking to apply the most cutting edge research and development strategies in the most efficient and robust manner.

Wellinks is the COPD disease management company providing individuals with the personalized care and support necessary for successful self-management. We prioritize the unique needs of each member to establish a clear path to better health. Our programs extend the reach of existing care resources, and fill gaps where they are absent. Respiratory specialists and our health coaches work one-on-one and across a community of members to personalize the experience and unlock the power of the individual in their journey to better health. Our care pathways are supported by a suite of innovative and simple to use technology, including a kit of connected devices and the Wellinks app, bridging the gap between doctor visits and allow patients to manage their COPD from wherever life takes them. Wellinks provides a welcoming and inclusive environment where members trust they will receive the best possible care and guidance in managing their COPD. Our solution is intuitive, engaging, and fully integrated across the care journey — empowering patients with the peace of mind and freedom to live fully and breathe freely.